Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Sierra Oncology Inc. (SRRA)

15.48   -0.15 (-0.96%) 02-14 16:00
Open: 15.91 Pre. Close: 15.63
High: 16.0113 Low: 15.13
Volume: 35,223 Market Cap: 161M
Sierra Oncology Inc is a clinical-stage drug development company engaged in next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.026 - 16.114 16.114 - 16.187
Low: 14.924 - 15.03 15.03 - 15.118
Close: 15.317 - 15.482 15.482 - 15.619

Technical analysis

as of: 2020-02-14 4:32:47 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 19.44     One year: 22.99
Support: Support1: 11.73    Support2: 9.76
Resistance: Resistance1: 16.64    Resistance2: 19.68
Pivot: 13.47
Moving Average: MA(5): 15.25     MA(20): 13.69
MA(100): 13.67     MA(250): 30.43
MACD: MACD(12,26): 0.19     Signal(9): -0.19
Stochastic oscillator: %K(14,3): 81.52     %D(3): 81.20
RSI: RSI(14): 56.35
52-week: High: 80.40  Low: 8.64  Change(%): -77.2
Average Vol(K): 3-Month: 7332  10-Days: 7684

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
SRRA has closed below upper band by 16.5%. Bollinger Bands are 3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.

Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1,…

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 1.87
Shares Float (M) 1.51
% Held by Insiders 0.15
% Held by Institutions 7.50
Shares Short (K) 154
Shares Short P. Month (K)

Stock Financials

EPS -29.560
Book Value (p.s.) 31.520
PEG Ratio -0.01
Profit Margin
Operating Margin
Return on Assets (ttm) -36.9
Return on Equity (ttm) -66.4
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -30.219
Qtrly Earnings Growth
Operating Cash Flow (M) -48.70
Levered Free Cash Flow (M) -29.39

Stock Valuations

P/E -0.52
P/E Growth Ratio -0.01
P/BV 0.49
P/CF -0.59

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2020-01-22
Last Split Ratio 0.025
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.